BB Biotech AG Asset Resilience Ratio
BB Biotech AG asset resilience ratio. BB Biotech AG (BION) has an Asset Resilience Ratio of 92.97% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of BB Biotech AG to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BB Biotech AG (2012–2025)
Asset resilience ratio of BB Biotech AG from 2012 to 2025. This chart shows how BB Biotech AG's Asset Resilience Ratio has changed over time. Read BION total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BB Biotech AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BB Biotech AG (BION) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF2.87 Billion | 92.97% |
| Total Liquid Assets | CHF2.87 Billion | 92.97% |
Asset Resilience Insights
- Very High Liquidity: BB Biotech AG maintains exceptional liquid asset reserves at 92.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BB Biotech AG Industry Peers by Asset Resilience Ratio
Compare BB Biotech AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
BB Biotech AG Asset Resilience Ratio by Year (2012–2025)
BB Biotech AG asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for BB Biotech AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.04% | CHF1.20 Million ≈ $1.51 Million |
CHF2.79 Billion ≈ $3.52 Billion |
-99.95pp |
| 2024-12-31 | 100.00% | CHF2.41 Billion ≈ $3.04 Billion |
CHF2.41 Billion ≈ $3.04 Billion |
+0.07pp |
| 2023-12-31 | 99.93% | CHF2.64 Billion ≈ $3.33 Billion |
CHF2.64 Billion ≈ $3.33 Billion |
+0.46pp |
| 2022-12-31 | 99.47% | CHF3.04 Billion ≈ $3.84 Billion |
CHF3.05 Billion ≈ $3.86 Billion |
-0.47pp |
| 2021-12-31 | 99.94% | CHF3.64 Billion ≈ $4.60 Billion |
CHF3.64 Billion ≈ $4.61 Billion |
+0.03pp |
| 2020-12-31 | 99.90% | CHF3.96 Billion ≈ $5.01 Billion |
CHF3.96 Billion ≈ $5.01 Billion |
+0.04pp |
| 2019-12-31 | 99.86% | CHF3.55 Billion ≈ $4.49 Billion |
CHF3.55 Billion ≈ $4.49 Billion |
-0.11pp |
| 2018-12-31 | 99.97% | CHF3.09 Billion ≈ $3.90 Billion |
CHF3.09 Billion ≈ $3.90 Billion |
+0.06pp |
| 2017-12-31 | 99.91% | CHF3.63 Billion ≈ $4.60 Billion |
CHF3.64 Billion ≈ $4.60 Billion |
+0.37pp |
| 2016-12-31 | 99.54% | CHF3.21 Billion ≈ $4.06 Billion |
CHF3.23 Billion ≈ $4.08 Billion |
+0.36pp |
| 2015-12-31 | 99.18% | CHF4.11 Billion ≈ $5.20 Billion |
CHF4.14 Billion ≈ $5.24 Billion |
-0.43pp |
| 2014-12-31 | 99.62% | CHF3.52 Billion ≈ $4.45 Billion |
CHF3.53 Billion ≈ $4.47 Billion |
+1.64pp |
| 2013-12-31 | 97.98% | CHF2.17 Billion ≈ $2.74 Billion |
CHF2.21 Billion ≈ $2.80 Billion |
+0.18pp |
| 2012-12-31 | 97.80% | CHF1.34 Billion ≈ $1.70 Billion |
CHF1.37 Billion ≈ $1.74 Billion |
-- |
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more